← All trials
NCT04610359
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 20, 2020
- Primary completion
- Oct 31, 2022
- Completion date
- Dec 31, 2022
- First posted
- Oct 30, 2020
- Last posted
- Oct 30, 2020
- Enrollment
- 3
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of UlsanLead sponsor
- University of UlsanReponsible party - principal investigator
- University of UlsanOverall official - principal investigator
- MIRAE CELL BIOCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.